Message from the CEO
IBT are currently in the completion stage of the phase II clinical trial (NCT02472769) and are concurrently working with preparations for a subsequent phase III clinical trial. The phase II clinical trial is a placebo controlled safety and tolerability study and part of the clinical program for IBP-9414. The final patient, of in total 120, was recruited on January 23, 2017 which means that patient follow-up is terminated and that results from the study are expected during the autumn of this year.
IBT is continuing the work to prepare for the application for admittance for trading of IBT's class B shares on the main marketplace, Nasdaq Stockholm. One step toward Nasdaq Stockholm main marketplace was IBT's application of listing on Nasdaq First North Premier, and completion of such listing change on March 14, 2017.
As previously stated, the phase III study will require additional capital. IBT is working very actively with several potential financing possibilities and partners who can contribute resources for the continuing development program.
|Operating profit/loss||-13 826||-10 975||-22 510||-16 078||-38 090|
|Result after tax||-13 827||-11 119||-22 511||-16 284||-38 106|
|Total assets||92 224||133 127||92 224||133 127||110 109|
|Cash flow for the period||-8 350||78 755||-17 463||71 973||49 375|
|Cash||76 323||116 384||76 323||116 384||93 786|
|Earnings per share, weighted average, before and after dilution (SEK)||-2,51||-2,84||-4,09||-6,44||-8,42|
|Equity per share (SEK)||15,19||23,08||15,19||23,08||19,12|
|Equity ratio (%)||91%||95%||91%||95%||96%|
Significant events during the second quarter 2017
Significant events during the reporting period January - June 2017
Significant events after the reporting period
Infant Bacterial Therapeutics AB (publ) Interim Report is now available on the companies website www.ibtherapeutics.com .
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis ("NEC"), a fatal, rare disease that can afflict premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.
IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.
For additional information please contact
Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 8 410 145 55
This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08.00 CET on September 28, 2017.